NCT05634044

Brief Summary

Monitoring dietary intake and digestion is important for both medical monitoring and assessing the wellness of individuals. Fiber is an important nutrient that is not focused on enough, despite it being an essential nutrient for the bacteria and other micro-organisms that reside in our GI Tracts, known as the microbiome. Ingestion of fermentable soluble and insoluble dietary fiber has been shown to result in the production of short-chain fatty acids (SCFA) by the colonic microbiome. These SCFAs are volatile organic compounds (VOCs) and can be detected in the atmosphere of a bowel movement. We have developed an e-Nose device that once placed in the bathroom records volatile organic compounds (VOCs) from the ambient air. We have demonstrated in an "N of 1" study a strong correlation between the eNose output and grams of daily fiber intake. The current study is being proposed to validate the e-Nose device on a larger population. This is a nonmedical device that is not regulated by the FDA. A total of 40 subjects are invited to participate in this 3-week study. Participants will be asked to complete questionnaires and provide stool and blood samples. The subjects will place the eNose device in their bathroom and record their daily food intake over a 3-week period.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
22

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Nov 2022

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 8, 2022

Completed
7 days until next milestone

First Submitted

Initial submission to the registry

November 15, 2022

Completed
16 days until next milestone

First Posted

Study publicly available on registry

December 1, 2022

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 13, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 13, 2023

Completed
Last Updated

May 29, 2024

Status Verified

May 1, 2024

Enrollment Period

11 months

First QC Date

November 15, 2022

Last Update Submit

May 24, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Accuracy of this device to detect increased intake of fiber

    Assessed by comparing percentage change in volatile organic compounds (measured in OHMS) against the daily fiber intake in grams

    3 weeks

Secondary Outcomes (3)

  • Ability of eNose to detect increased production of SCFA- positive correlation between enose signals and each of three SCFA and total SCFA levels in stool

    3 weeks

  • Impact of fiber bar in microbiota composition

    3 weeks

  • Tolerability of prebiotic bar

    3 weeks

Study Arms (1)

eNose device use

EXPERIMENTAL

Participants will place the e-Nose device in their bathroom to record VOCs from the ambient air after they have a bowel movement. In addition to this, all participants will complete 2 blood draws 3 stool collections, and questionnaires over the course of 4 visits during a 3 week period.

Device: eNose Device

Interventions

Participants will place the e-Nose device in their bathroom to record VOCs from the ambient air after they have a bowel movement. In addition to this, all participants will complete 2 blood draws 3 stool collections and questionnaires over the course of 4 visits during a 3-week period.

eNose device use

Eligibility Criteria

Age21 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Males and females, age 21-65, with no chronic medical diseases (mild and controlled hypertension, and controlled hyperlipidemia are acceptable).
  • Willingness to eat 2 prebiotic bar per day for two weeks and collect stool samples three times, provide blood samples twice and complete questionnaires.

You may not qualify if:

  • Patients on a restricted diet (e.g., gluten-free diet, Paleo diet, vegetarian or vegan diet)
  • Allergy to almonds, flax seed, or coconuts
  • Chronic GI disorders (Inflammatory bowel disease, Irritable Bowel Syndrome on regular therapy taking fiber or MiraLAX is acceptable to be enrolled; celiac disease, colon cancer, intestinal resection,)
  • Chronic NSAID use (more than 3 days per week)
  • Antibiotic use in the last 12 weeks
  • BMI \> 35 or \< 18
  • Inability to sign an informed consent form
  • Non-English speaker

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Rush University Medical Center

Chicago, Illinois, 60612, United States

Location

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DEVICE FEASIBILITY
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principle Investigator

Study Record Dates

First Submitted

November 15, 2022

First Posted

December 1, 2022

Study Start

November 8, 2022

Primary Completion

October 13, 2023

Study Completion

October 13, 2023

Last Updated

May 29, 2024

Record last verified: 2024-05

Locations